nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial

PURPOSE: The global Phase III MPACT trial demonstrated superior efficacy of nab-paclitaxel plus gemcitabine over gemcitabine alone as first-line treatment for metastatic pancreatic cancer. Region was a randomization stratification factor in the MPACT trial. This subgroup analysis of MPACT examined e...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Onco Targets Ther
Egile Nagusiak: Tabernero, Josep, Kunzmann, Volker, Scheithauer, Werner, Reni, Michele, Shiansong Li, Jack, Ferrara, Stefano, Djazouli, Kamel
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove Medical Press 2017
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5295788/
https://ncbi.nlm.nih.gov/pubmed/28203092
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S124097
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak